Healthcare

November 10, 2019

Moroccan Pension Fund to Buy 5 University Hospital Centers

Rabat – The Moroccan Minister of Economy and Finance, Mohamed Benchaaboun, announced that the Moroccan Pension Fund (CMR) will buy five university hospital centers (CHU). Benchaaboun has not disclosed the hospitals’ names. Benchaaboun made the announcement at a press conference"...

November 10, 2019

Moroccan Parliament Debates Progressive Sugar Tax

Rabat – As Morocco’s 2020 Finance Bill is under review by Parliament, debate has sparked regarding progressive measures to ensure the health of Moroccan citizens.

The internal consumption tax (ICT),"...

November 10, 2019

Morocco Inks Nuclear Medicine Agreement with International Partners

Rabat – The minister of Energy, Hydrocarbons, and the environment Aziz Rabbah signed a Memorandum of Understanding (MoU) with the National Center for Energy and Nuclear Science and Technology (CNSTN), the American Long Island University, France’s Dassault Systemes, and the national"...

November 10, 2019

Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (Takeda) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved......

November 8, 2019

New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in patients with hereditary angioedema (HAE) 12 years of age and older studied in the ongoing Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses, being presented at the 2019 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting in Houston, Texas from November 7-11, showed that TAKHZYRO continued to prevent HAE attacks at a rate similar to that observed......

November 7, 2019

Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure

− New England Journal of Medicine publishes primary endpoint analysis from ongoing Phase 3 study of Takeda’s dengue vaccine candidate

− Over 20,000 study participants in dengue-endemic areas in Latin America and Asia received two doses of Takeda’s dengue"...

November 7, 2019

Fakih IVF Oman celebrates 49th Oman National Day

Fakih IVF Fertility Center in Oman has recently witnessed an increase in number of patients battling infertility, over 800 patients have been treated since its inception. Doctors at the center suggest that the inability to conceive in certain cases is due to female factors and in many others"...

November 7, 2019

Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singen vaccine plant will be utilized for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line. Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant. According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease, which is estimated to cause approximately 390 million infections and 20,000......

November 6, 2019

Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates

Agreement with Biogen covers Samsung Bioepis’ biosimilar candidates in pre-clinical and clinical development, which reference two widely-used biologic medicines in ophthalmology: ranibizumab and aflibercept
Includes an option for Biogen to extend existing commercialization agreement for Samsung Bioepis’ anti-TNF medicines in Europe...

November 6, 2019

Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005250/en/ Under the agreement, Takeda will receive access to MD Anderson’s CAR NK platform and the exclusive rights to develop......